At Miami Cancer Institute, every lung cancer patient receives molecular analysis to better understand the cancer subtype and help identify the best treatment plan using immunotherapy and other advanced therapies. We believe this is a critical step, as every lung cancer case is different, and modern treatment methods depend on careful and accurate analysis.
An important step to reducing your risk of cancer and staying healthy is by getting your recommended screenings.
Miami Cancer Institute has activated its preparedness protocols to help screen, identify and safely treat any potential cases of COVID-19.
Miami Cancer Institute is here to help you every step of the way after a cancer diagnosis.
If you're a physician with a patient you'd like us to help care for, we're ready to collaborate with you.
Miami Cancer Institute can provide access to clinical trials not widely available elsewhere. Clinical trials find new ways to treat and diagnose cancer and are ongoing. If an appropriate trial is available, we will talk to you about the benefits and risks.
Mark Dylewski, M.D., is a thoracic and robotic surgeon at Miami Cancer Institute, a part of Baptist Health South Florida. He is a graduate of the University of Miami Miller School of Medicine and completed residencies at the University of California Davis-East Bay and the University of Albany Medical Center. Dr. Dylewski is an expert in minimally invasive thoracic surgery. He is Board-certified in general surgery and thoracic surgery and is one of the country's pioneers in the area of robotic pulmonary and esophageal surgery. He developed the complete port access robotic-assisted technique using the da Vinci robot to perform pulmonary and esophageal surgery without spreading the ribs, an innovative procedure that is being adopted by other surgeons. Dr. Dylewski's research and clinical results have been published in peer-reviewed scientific journals, including Seminars in Thoracic and Cardiovascular Surgery, Journal of Robotic Surgery and the Annals of Thoracic Surgery.
As Florida's only member of the Memorial Sloan Kettering (MSK) Cancer Alliance, Miami Cancer Institute is part of a deep and functional collaboration that affords patients access to innovative treatments right here at home and ensures that the standards of care developed by our multidisciplinary disease management team match those at MSK.